Last reviewed · How we verify
IMJUDO (TREMELIMUMAB-ACTL)
IMJUDO (generic name: TREMELIMUMAB-ACTL) is a CTLA-4-directed Blocking Antibody [EPC] drug developed by ASTRAZENECA AB. It is currently FDA-approved for Liver cell carcinoma, Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations, Non-small cell lung cancer, negative for epidermal growth factor receptor expression.
At a glance
| Generic name | TREMELIMUMAB-ACTL |
|---|---|
| Sponsor | ASTRAZENECA AB |
| Drug class | CTLA-4-directed Blocking Antibody [EPC] |
| Target | Cytotoxic T-lymphocyte protein 4 |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Liver cell carcinoma
- Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations
- Non-small cell lung cancer, negative for epidermal growth factor receptor expression
Common side effects
- Nausea
- Rash
- Diarrhea
- Decreased appetite
- Fatigue
- Pruritus
- Musculoskeletal pain
- Abdominal pain
Serious adverse events
- Hemorrhage
- Diarrhea
- Sepsis
- Pneumonia
- Rash
- Vomiting
- Acute kidney injury
- Anemia
- Death
- Hemorrhage intracranial
Key clinical trials
- Proton Radiotherapy Combined With Tremelimumab and Durvalumab for BCLC Stage B and C Hepatocellular Carcinoma (Phase 2)
- A Phase 2 Study on Immune Checkpoint Inhibitors and Radioembolisation for Previously Untreated Metastatic Hepatocellular Carcinoma (Phase 2)
- A Phase I/IIa, Single-arm, Open-label, IIT for Safety and Efficacy Evaluation of Tremelimumab Plus Durvalumab(MEDI4736) in Combination With Concurrent Transarterial Chemoembolization in Unresectable H (Phase 1)
- Specific Use-results Study of IMJUDO Intravenous Infusion 25mg / IMFINZI Intravenous Infusion 120mg,500mg All Patient Investigation in Patients With Unresectable Advanced or Recurrent Non-small Cell L (N/A)
- Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Tr (Phase 2)
- A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer (Phase 2)
- Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC (Phase 3)
- Specific Use-results Study of IMJUDO Intravenous Infusion 25 mg, 300 mg / IMFINZI Intravenous Infusion 120 mg, 500 mg All Patient Investigation in Patients With Unresectable Hepatocellular Carcinoma (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMJUDO CI brief — competitive landscape report
- IMJUDO updates RSS · CI watch RSS
- ASTRAZENECA AB portfolio CI
Frequently asked questions about IMJUDO
What is IMJUDO?
IMJUDO (TREMELIMUMAB-ACTL) is a CTLA-4-directed Blocking Antibody [EPC] drug developed by ASTRAZENECA AB, indicated for Liver cell carcinoma, Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations, Non-small cell lung cancer, negative for epidermal growth factor receptor expression.
What is IMJUDO used for?
IMJUDO is indicated for Liver cell carcinoma, Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations, Non-small cell lung cancer, negative for epidermal growth factor receptor expression.
Who makes IMJUDO?
IMJUDO is developed and marketed by ASTRAZENECA AB (see full ASTRAZENECA AB pipeline at /company/astrazeneca).
What is the generic name of IMJUDO?
TREMELIMUMAB-ACTL is the generic (nonproprietary) name of IMJUDO.
What drug class is IMJUDO in?
IMJUDO belongs to the CTLA-4-directed Blocking Antibody [EPC] class. See all CTLA-4-directed Blocking Antibody [EPC] drugs at /class/ctla-4-directed-blocking-antibody-epc.
What development phase is IMJUDO in?
IMJUDO is FDA-approved (marketed).
What are the side effects of IMJUDO?
Common side effects of IMJUDO include Nausea, Rash, Diarrhea, Decreased appetite, Fatigue, Pruritus. Serious adverse events: Hemorrhage, Diarrhea, Sepsis, Pneumonia.
What does IMJUDO target?
IMJUDO targets Cytotoxic T-lymphocyte protein 4 and is a CTLA-4-directed Blocking Antibody [EPC].
Related
- Drug class: All CTLA-4-directed Blocking Antibody [EPC] drugs
- Target: All drugs targeting Cytotoxic T-lymphocyte protein 4
- Manufacturer: ASTRAZENECA AB — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Liver cell carcinoma
- Indication: Drugs for Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations
- Indication: Drugs for Non-small cell lung cancer, negative for epidermal growth factor receptor expression
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing